Sign In
16 OCT 2015 - Terumo BCT Announces Implementation of Correct Connect System
10/16/2015

​​A new connection system is designed to simplify apheresis procedures and help improve safety by standardizing connections between solutions and tubing sets

LAKEWOOD, Colo., USA—16 October 2015—Terumo BCT launched the Correct Connect System, a new, standardized connection system for the solutions used during apheresis procedures. The Correct Connect system was established by the addition of a new connector for anticoagulant, designed by Terumo BCT in collaboration with other apheresis manufacturers. The Correct Connect system is supported by industry and blood establishments and is expected to be the global standard for apheresis connections.

Created to reduce the potential for accidental misconnections, the Correct Connect system introduces a new, inverted threaded-luer connector for use with anticoagulant solution. This addition means that there is now a dedicated connection method for each type of solution used during apheresis—including anticoagulant, platelet additive solution, red blood cell additive solution and saline. The connectors currently used for additive solutions and saline will not change.

The Correct Connect system:

  • Simplifies the connection of all apheresis solutions by establishing a new, distinctive connector for anticoagulant solutions; each type of solution used during apheresis now has available a unique connection type

  • Helps prevent the misconnection of apheresis solutions during apheresis procedures because the connector for each type of solution is incompatible with the others

  • Reduces the opportunity for leaking between the anticoagulant bag and the tubing set

"I am proud of the collaboration with our industry partners and customers. Working together, we are able to deliver higher levels of quality, safety and efficiency," said Tom Jordan, Executive Vice President of Global Commercial Operations, Terumo BCT. "The Correct Connect system is a great example of Terumo BCT's commitment to continuous improvement for our customers, donors and the patients we ultimately serve."

The International Standards Organization (ISO) Committee TC210/WG5 is currently working on the new standard for the anticoagulant connector, which has been assigned the number ISO 18250-8.

Health care professionals using the Trima Accel® Automated Blood Collection System and the Spectra Optia® Apheresis System, both from Terumo BCT, can expect to see the new system implemented in their markets based on geographical region and regulatory approvals.

KEY FACTS:

  • The Correct Connect system simplifies the connection of all apheresis solutions and provides an additional safety measure for donors and patients.

  • The design for the connector was made by employees of CaridianBCT and dedicated to the public by publication. Terumo BCT is the successor in interest of CaridianBCT. The publication is available at IP.com as disclosure number IPCOM000213128D, published 05 December 2011. No license is required.

  • The Correct Connect system is supported by the apheresis industry and blood establishments.

  • The Apheresis Industry Working Group is open to all apheresis equipment, component and additive solutions manufacturers; current participating members include Cerus, the European Blood Alliance (EBA), Fresenius Kabi, Grifols, Haemonetics, Macopharma, Qosina, Scinomed, Technoflex, Terumo BCT and Therakos.

  • The International Standards Organization (ISO) Committee TC210/WG5 is currently working on the new standard for the anticoagulant connector, which has been assigned the number ISO 18250-8

  • The Correct Connect system[1] will be introduced into the marketplace based on geographical region and regulatory approvals.

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

Contact:
D.J. Martin
Global Corporate Communications
Phone: +1.303.239.2060
press@terumobct.com


[1] Available in select markets​